Twitter Facebook LinkedIn
Center for Global Research Data

Predicting outcomes (death, improvement, survival) of COVID-19 patients on Standard of Care (SoC)

Lead Investigator: Andreas Artemiou, Cardiff University
Title of Proposal Research: Predicting outcomes (death, improvement, survival) of COVID-19 patients on Standard of Care (SoC) .
Vivli Data Request: 7325
Funding Source: None
Potential Conflicts of Interest: Dr. Crompton-Brown’s placement as a statistical analyst at UCB came to an end on the 27th of August 2021 and they no longer have any access to any UCB company-related matters or systems.

Summary of the Proposed Research:
As of 4th August 2021, the Office of National Statistics (ONS) estimates 496018 patients have been in UK hospitals with COVID-19 and 153734 have died. Whilst hospital rates and deaths are no longer peaking and have been blunted by the UK vaccination program it is important to understand the risk factors associated with poor COVID-19 outcomes.

This project will help further our understanding of COVID-19 and how we can begin to predict the outcome of a patient from their baseline hospital admission data in a clinical trial setting. This could be extended to the general hospitalized COVID-19 population helping to identify high risk patients as early as possible.

Requested Studies:
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Data Contributor: Roche
Study ID: NCT04320615
Sponsor ID: WA42380

A Phase-II, Open-Label, Randomized, Multicenter Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of 8 mg/kg or 4mg/kg Intravenous Tocilizumab in Patients With Moderate to Severe COVID-19 Pneumonia
Data Contributor: Roche
Study ID: NCT04363736
Sponsor ID: CA42481

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Patients With COVID-19 Pneumonia
Data Contributor: Roche
Study ID: NCT04372186
Sponsor ID: ML42528

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of MSTT1041A or UTTR1147A in Patients With Severe COVID-19 Pneumonia
Data Contributor: Roche
Study ID: NCT04386616
Sponsor ID: GA42469

Treating COVID-19 With Hydroxychloroquine: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial in Hospitalized Adults
Data Contributor: NYU Grossman School of Medicine
Study ID: NCT04369742
Sponsor ID: 20-00463

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease: A Randomized Clinical Trial
Data Contributor: University Medical Center, New Orleans
Study ID: NCT04344444
Sponsor ID: COVID 2020-001

A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia
Data Contributor: Roche
Study ID: NCT04409262
Sponsor ID: WA42511